HIV Infections Clinical Trial
Official title:
IMARA, Adapting SiHLE for Detained African American Adolescent Females
The IMARA Program will test the efficacy of a multi-session HIV Prevention program, adapted from an existing program(SiHLE), for incarcerated African American adolescent females.
African American adolescent females in youth detention centers are at high risk for HIV
infection. There are, however, no evidence-based interventions (EBI) for this vulnerable
population. The aim of this project is to develop and test a culturally and
gender-appropriate sexual health education program designed to promote HIV preventive sexual
behaviors among African American adolescent females in youth detention centers. The study
will be conducted in four stages: (1) adaptation of SiHLE intervention; (2) pilot adapted
intervention; (3) revisions to adapted intervention, measures, and implementation; and (4)
implementation and evaluation.
We will work closely with the Metro Regional Youth Detention Center (RYDC), in Atlanta,
Georgia for all four stages of the project. The first stage, adaptation of SiHLE
intervention, will be implemented using data collected from a prior study and with use of
Community and Teen Advisory Boards (CAB and TAB). The pilot intervention will be completed
with 20 participants from Metro RYDC and will test recruitment and retention strategies, the
adapted intervention, and all measures. Revisions will be made based on findings from the
pilot. For stage four, implementation and evaluation, we propose to recruit 350 unmarried
African American adolescent females, 13-17 years of age, from Metro RYDC. While at the Metro
RYDC, adolescents will be invited to participate in the proposed study. All adolescents will
be required to have verbal informed parental/guardian consent and complete signed assent
forms. Adolescents who are eligible and willing to participate in the project will complete
an initial survey conducted on a computer(ACASI). The survey is designed to assess
adolescents' sexual risk and preventive behaviors. After they complete the survey,
adolescents will then be assigned, by chance alone, to receive either the adapted SiHLE
intervention or the control condition. All adolescents will complete 3 individual sessions
implemented by an African American health educator.
As we anticipate the participants will be released prior to the follow-up assessment,
adolescents will come to a central community site to complete follow-up interviews at 3 and
6-months after completing their initial survey. We will also obtain a self-collected vaginal
swab specimen to test for chlamydia and gonorrhea. We will compare the new adapted SiHLE
intervention, IMARA, to the control condition in its ability to maintain or enhance
adolescents' use of HIV prevention behaviors. If successful, the findings could have
important implications for HIV prevention in this vulnerable population.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |